PitchSend

Healthy Growth across all verticals in FY'22

Unique value propositions дю BETA Brugs DRUGS LTD. Diversified Oncology portfolio ET 6'9 Lung Cancer Head & Neck Cancer Colorectal Cancer Strong Future pipeline Rich product pipeline of 23 products Differentiated Science/Innovation Working on ⚫NDDS •TKIs •Proteasome inhibitors •PARP inhibitors Backwardly Integrated BDL is among the few companies that work across the value chain Developed API of 90% of own brands Breast Cancer Gastric Cancer Ав 360 Brain Tumor Testicular Cancer Renal Cancer Ovarian Cancer Leukemia Lymphoma Myeloma Supportive Prostate Cancer Hemat Solid 2021 2022 2023 2024 2025 2026 3 2 NIB'S New Drug Delivery System PARP Inhibitors 4

View entire presentation